Non-Alcoholic Fatty Liver Disease Pipeline Analysis 2025 By Delveinsight Guangdong Raynovent Biotech, Dr. Falk Pharma Gmbh, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma

(MENAFN- GetNews)


"Non-Alcoholic Fatty Liver Disease Pipeline"DelveInsight's,“Non-Alcoholic Fatty Liver Disease - Pipeline Insight, 2025” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Non-Alcoholic Fatty Liver Disease (NAFLD) pipeline features 90+ prominent companies actively developing over 100 treatment therapies.

Non-Alcoholic Fatty Liver Disease Overview:

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders marked by the accumulation of fat within liver cells (macrovesicular steatosis), detected through imaging or biopsy, without other identifiable causes such as excessive alcohol intake, prolonged use of liver-toxic medications, or genetic conditions. In Western countries, NAFLD affects about 20–30% of the population.

The condition is strongly associated with risk factors including obesity, type 2 diabetes, dyslipidemia, insulin resistance, and metabolic syndrome. Research has also indicated a potential link between exposure to inorganic arsenic and NAFLD, evidenced by elevated alanine aminotransferase (ALT) levels. Since NAFLD is closely connected to metabolic syndrome, it often coexists with cardiovascular risk factors. Along with the possibility of progressing to cirrhosis and hepatocellular carcinoma, these complications significantly contribute to mortality in affected patients.

Download our report @

"Non-Alcoholic Fatty Liver Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Alcoholic Fatty Liver Disease Therapeutics Market.

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report

• DelveInsight's report on the Non-Alcoholic Fatty Liver Disease (NAFLD) pipeline highlights a dynamic landscape, with more than 90 companies actively developing over 100 therapeutic candidates.

• In March 2024, the U.S. FDA granted accelerated approval to Rezdiffra (resmetirom) for adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. This landmark decision made Rezdiffra the first approved treatment specifically for NASH, also referred to as metabolic dysfunction-associated steatohepatitis (MASH).

• Leading companies driving innovation in this space include Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca, among others.

• Noteworthy therapies currently in various phases of development include Lanifibranor, ZED 1227, TVB-2640, ALS-L1023, AZD9550, and additional promising candidates.

Non-Alcoholic Fatty Liver Disease Pipeline Analysis

The Non-Alcoholic Fatty Liver Disease pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Non-Alcoholic Fatty Liver Disease Market.

• Categorizes Non-Alcoholic Fatty Liver Disease therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Non-Alcoholic Fatty Liver Disease drugs under development based on:

  • Stage of development

  • Non-Alcoholic Fatty Liver Disease Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Non-Alcoholic Fatty Liver Disease Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Non-Alcoholic Fatty Liver Disease Licensing agreements

  • Funding and investment activities supporting future Non-Alcoholic Fatty Liver Disease market advancement.

Request for a sample report @

Non-Alcoholic Fatty Liver Disease Emerging Drugs

• Lanifibranor: Inventiva Pharma

• ZED 1227: Dr. Falk Pharma GmbH

• TVB-2640: Sagimet Biosciences

• ALS-L1023: AngioLab

• AZD9550: AstraZeneca

Non-Alcoholic Fatty Liver Disease Companies

Nearly 90 prominent companies are engaged in developing therapies for Non-Alcoholic Fatty Liver Disease (NAFLD), with Inventiva Pharma advancing one of its drug candidates to the most advanced stage-Phase III clinical trials.

DelveInsight's report covers around 100+ products under different phases of Non-Alcoholic Fatty Liver Disease clinical trials like

• Non-Alcoholic Fatty Liver Disease Late stage Therapies (Phase III)

• Non-Alcoholic Fatty Liver Disease Mid-stage Therapies (Phase II)

• Non-Alcoholic Fatty Liver Disease Early-stage Therapies (Phase I)

• Non-Alcoholic Fatty Liver Disease Pre-clinical and Non-Alcoholic Fatty Liver Disease Discovery stage Therapies

• Non-Alcoholic Fatty Liver Disease Discontinued & Inactive Therapies

Non-Alcoholic Fatty Liver Disease pipeline report provides the Non-Alcoholic Fatty Liver Disease therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Alcoholic Fatty Liver Disease Therapies and Key Non-Alcoholic Fatty Liver Disease Companies: Non-Alcoholic Fatty Liver Disease Clinical Trials and recent advancements

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment

. Non-Alcoholic Fatty Liver Disease Assessment by Product Type

. Non-Alcoholic Fatty Liver Disease By Stage

. Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration

. Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type

Download Non-Alcoholic Fatty Liver Disease Sample report to know in detail about the Non-Alcoholic Fatty Liver Disease treatment market @ Non-Alcoholic Fatty Liver Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Non-Alcoholic Fatty Liver Disease Current Treatment Patterns

4. Non-Alcoholic Fatty Liver Disease - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Non-Alcoholic Fatty Liver Disease Late-Stage Products (Phase-III)

7. Non-Alcoholic Fatty Liver Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Alcoholic Fatty Liver Disease Discontinued Products

13. Non-Alcoholic Fatty Liver Disease Product Profiles

14. Non-Alcoholic Fatty Liver Disease Key Companies

15. Non-Alcoholic Fatty Liver Disease Key Products

16. Dormant and Discontinued Products

17. Non-Alcoholic Fatty Liver Disease Unmet Needs

18. Non-Alcoholic Fatty Liver Disease Future Perspectives

19. Non-Alcoholic Fatty Liver Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-Alcoholic Fatty Liver Disease Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN01092025003238003268ID1110002618